Trial Profile

An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acoramidis (Primary)
Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
Focus Adverse reactions; Registrational
Acronyms ATTRibute-CM OLE
Sponsors BridgeBio Pharma; Eidos Therapeutics

Most Recent Events

18 Nov 2024 Results presented in a BridgeBio Pharma media release.
18 Nov 2024 According to a BridgeBio Pharma Media Release, the preliminary results from this ongoing OLE study were also simultaneously published in Circulation.
18 Nov 2024 According to a BridgeBio Pharma media release, the company presented positive initial outcomes from the study at the American Heart Association (AHA) Scientific Sessions.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com